Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

被引：0
|
作者：
Boussion, H. [1 ]
Hammel, P. [2 ]
机构：
[1] AERIO, Tokyo, Japan
[2] Hop Beaujon, Clichy, France
来源：
ONCOLOGIE | 2015年 / 17卷 / 1-2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：59 / 60
页数：2
相关论文
共 50 条
  • [31] Clinical utility of lanreotide Autogel® in gastroenteropancreatic neuroendocrine tumors
    Paragliola, Rosa Maria
    Prete, Alessandro
    Papi, Giampaolo
    Torino, Francesco
    Corsello, Andrea
    Pontecorvi, Alfredo
    Corsello, Salvatore Maria
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 3459 - 3470
  • [32] Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors
    Wolin E.M.
    Manon A.
    Chassaing C.
    Lewis A.
    Bertocchi L.
    Richard J.
    Phan A.T.
    Journal of Gastrointestinal Cancer, 2016, 47 (4) : 366 - 374
  • [33] Quality of Life (QoL) with Lanreotide Autogel/Depot (LAN) vs. Placebo in Patients with Enteropancreatic Neuroendocrine Tumors: Results From the CLARINET Core Study
    Ruszniewski, Philippe
    Phan, Alexandria T.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    PANCREAS, 2015, 44 (02) : 357 - 357
  • [34] Molecular evidence for independent origin of multifocal neuroendocrine tumors of the enteropancreatic axis
    Katona, Terrence M.
    Jones, Timothy D.
    Wang, Mingsheng
    Abdul-Karim, Fadi W.
    Cummings, Oscar W.
    Cheng, Liang
    CANCER RESEARCH, 2006, 66 (09) : 4936 - 4942
  • [35] Activation of the Serine/Theronine Protein Kinase Akt in Enteropancreatic Neuroendocrine Tumors
    Ghayouri, Masoumeh
    Boulware, David
    Nasir, Aejaz
    Strosberg, Jonathan
    Kvols, Larry
    Coppola, Domenico
    ANTICANCER RESEARCH, 2010, 30 (12) : 5063 - 5067
  • [36] Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors
    Ito, Tetsuhide
    Honma, Yoshitaka
    Hijioka, Susumu
    Kudo, Atsushi
    Fukutomi, Akira
    Nozaki, Akira
    Kimura, Yasutoshi
    Motoi, Fuyuhiko
    Isayama, Hiroyuki
    Komoto, Izumi
    Hisamatsu, Seiichi
    Nakajima, Akihiro
    Shimatsu, Akira
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (04) : 499 - 508
  • [37] Evaluation of the antiproliferative effect of lanreotide or interferon-alpha or the combination of both in the therapy of metastatic neuroendocrine tumors.
    Faiss, S
    Riecken, EO
    Wiedenmann, B
    GASTROENTEROLOGY, 1998, 114 (04) : A593 - A593
  • [38] An update on the safety of lanreotide autogel for the treatment of patients with neuroendocrine tumors
    Sood, Aayushi
    Munir, Malak
    Syed, Omar
    Mehta, Vidhi
    Kaur, Ravleen
    Kumar, Arathi
    Sridhar, Archana
    Sood, Akshit
    Gupta, Rahul
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (08) : 949 - 957
  • [39] Pharmacokinetic Behavior of Lanreotide Autogel in Patients with Carcinoid Neuroendocrine Tumors
    Ramis, J.
    Cendros, J. M.
    Peraire, C.
    Obach, R.
    Lesage, C.
    NEUROENDOCRINOLOGY, 2009, 90 (01) : 133 - 134
  • [40] Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors
    Tetsuhide Ito
    Yoshitaka Honma
    Susumu Hijioka
    Atsushi Kudo
    Akira Fukutomi
    Akira Nozaki
    Yasutoshi Kimura
    Fuyuhiko Motoi
    Hiroyuki Isayama
    Izumi Komoto
    Seiichi Hisamatsu
    Akihiro Nakajima
    Akira Shimatsu
    Investigational New Drugs, 2017, 35 : 499 - 508
12345